Dexcom (DXCM)President & COO bought ~$863K

~$863K

Approx. value · 16K sh @ $54.98

329K

Holds after · shares reported

Traded

Nov 10, 2025

Filed

Nov 11, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Sep 14, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“Effective September 14, 2025, Kevin R. Sayer, Chief Executive Officer (principal executive officer) and Chairman of the Board of DexCom, Inc. (“Dexcom” or the “Company”) is taking a temporary medical leave of absence.”
2. Oct 24, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On October 24, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to ten directors and appointed Dr. Euan Ashley as a director, effective immediately.”
3. Oct 27, 2025Court · District Court, S.D. New YorkSecurities lawsuit filed: Prime v. DexCom, Inc.
4. Oct 30, 2025Company filing · Form 8-K · ResultsReported its results
5. Oct 30, 20255% stakeThe Vanguard Group reported a passive stake (13G) of 12.6%
6. Nov 10, 2025 · this disclosureInsider · First insider buy since Nov 2017Officer purchased ~$863K of DXCM shares in the open market

What came next

1. Nov 10, 2025Court · District Court, S.D. New YorkSecurities lawsuit filed: Oakland County Employees Retirement System v. DexCom, Inc.
2. Nov 10, 2025Insider · 2 peopleInsiders: 1 purchase (~$139K), 1 sale (~$218K)
3. Nov 12, 2025InsiderDirector sold ~$59K of DXCM shares in the open market
4. Nov 14, 2025InsiderDirector sold ~$172K of DXCM shares in the open market
5. Nov 18, 2025FDAFDA device clearance: Dexcom Smart Basal
6. Nov 25, 2025Court · District Court, S.D. CaliforniaSecurities lawsuit filed: Boston Retirement System v. Dexcom, Inc.
7. Dec 17, 2025FDAFDA device clearance: Dexcom G7 Continuous Glucose Monitoring (CGM) System, Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System
8. Dec 19, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“As previously reported on the Current Report on Form 8-K filed on July 30, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jacob S. Leach, President and Chief Operating Officer, as the President and Chief Executive Officer and as a director of the Company, effective January 1, 2026, following Kevin R. Sayer’s resignation, effective as of such date.”
9. Jan 7, 2026Company filing · Form 8-K · ResultsReported its results
10. Jan 26, 2026CongressDisclosed purchase of DXCM — reported range $1,001 - $15,000
11. Feb 3, 2026FDAFDA device clearance: Dexcom G7 Continuous Glucose Monitoring (CGM) System; Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System
12. Feb 12, 2026Company filing · Form 8-K · ResultsReported its results
13. Feb 12, 2026InsiderDirector sold ~$69K of DXCM shares in the open market
14. Feb 26, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On February 26, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to twelve directors and appointed Albert F. (“Rick”) Osterloh, IV as a director effective immediately.”
15. Feb 27, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“As previously reported on the Current Report on Form 8-K filed on July 30, 2025, Kevin R. Sayer notified the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) of his intent to retire from his role as Chief Executive Officer effective January 1, 2026.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Dexcom

For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 16 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DXCM page.

Other recent filings by Jacob Steven Leach, President & COO

• SEC Form 4 at Senestech (SNES)Nov 20, 2025
• SEC Form 4 at Dexcom (DXCM)Nov 11, 2025
• SEC Form 4 at Dexcom (DXCM)Mar 14, 2025
• SEC Form 4 at Dexcom (DXCM)Jan 30, 2025
• SEC Form 4 at Dexcom (DXCM)Dec 17, 2024

The full history of Jacob Steven Leach, President & COO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Dexcom

• SEC Form 4Sep 30, 2026
• SEC Form 144Sep 28, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 144Sep 15, 2026

Everything OQRO holds on this company is on its DXCM page.